Select Your Region
Americas
Europa
Afrika
Weltweit
Charakterisierung der Einnahme von nicht-steroidalen Antirheumatika (NSAR) bei Teilnehmenden mit rheumatoider Arthritis (RA), die Tocilizumab (RoACTREMRA®) erhalten
Characterization of Non-Steroidal Anti-Inflammatory Drug (NSAID) Intake in Rheumatoid Arthritis (RA) Participants on Tocilizumab (RoACTEMRA®) Treatment (CONIFER)
- Autoimmunerkrankung
- Rheumatoide Arthritis
Bitte beachten Sie, dass der Rekrutierungsstatus der Studie an Ihrem Standort vom Gesamtstatus der Studie abweichen kann, da einige Studienzentren früher rekrutieren als andere.
Status der Studie:
Abgeschlossen
Diese Studie läuft in
Städte
- Altenburg
- Amberg
- Bad Nauheim
- Berlin
- Burghausen
- Dresden
- Düsseldorf
- Güstrow
- Halle (Saale)
- Hamburg
- Hannover
- Heidelberg
- Magdeburg
- Mansfeld
- München
- Neubrandenburg
- Offenburg
- Püttlingen
- Ratingen
- Saarbrücken
- Stuttgart
- Ulm
Studien-ID:
NCT03112213 ML30088
Studienzusammenfassung
This nationwide, multicenter, single arm, prospective, non-interventional study will evaluate the quantitative pattern of NSAID use and the impact of treatment with tocilizumab on NSAID use in a representative cohort of participant with moderate to severe active RA who have either responded inadequately to, or who were intolerant to previous therapy with one or more synthetic disease modifying anti-rheumatic drug (sDMARD), and for whom the physician has made the individual decision to initiate tocilizumab (subcutaneous [SC] or intravenous [IV]) as first biological disease modifying anti-rheumatic drug (DMARD) therapy according to the summary of product characteristics (SPC).
Hoffmann-La Roche
Sponsor
N/A
Phase
NCT03112213, ML30088
Studien-ID
Tocilizumab, NSAIDs
Treatments
Rheumatoid Arthritis
Condition
Official Title
CONIFER (Characterization of NSAID Intake for Established Rheumatoid Arthritis)
Einschlusskriterien
All
Gender
≥ 18 Years
Age
No
Healthy Volunteers
Inclusion Criteria
- Participants with moderate to severe active RA who have either responded inadequately to, or who were intolerant to, previous therapy with one or more sDMARDs and for whom the physician has made the individual decision to be treated with tocilizumab (SC or IV)
- Current users of NSAIDs due to RA as assessed by the physician
Exclusion Criteria
- Contraindications to treatment with tocilizumab as per SPC
- Prior therapy with tocilizumab
Um die aktuellste Version dieser Seite aufzurufen gehen Sie bitte auf www.Klinische-studien-für-patienten.de